10x Genomics Stock Is AI Pathology Tie Up A Real Oncology Catalyst

• In September 2026, Lunit announced that 10x Genomics will integrate Lunit SCOPE IO into its oncology biomarker discovery workflow, pairing AI analysis of H&E pathology images with spatial molecular data from Xenium and Atera platforms to support clinical research on antibody drug conjugates and immunotherapy response prediction.
• By combining AI-based tissue characterization from Lunit SCOPE IO with 10x Genomics spatial profiling, the partnership targets more granular insight into tumor microenvironments and treatment response patterns, which could influence how future oncology diagnostics and biomarker driven therapies are designed and evaluated.
• This development raises questions about how 10x Genomics use of AI powered pathology in spatial oncology research could reshape its broader investment narrative.

Scan beyond 10x Genomics and this Lunit partnership by sizing up hand-picked peers at the intersection of cancer research and machine learning through the 39 healthcare AI stocks.

10x Genomics Investment Narrative Recap

To own 10x Genomics, you need to believe that demand for single cell, spatial, and multiomic tools keeps broadening and that this portfolio can translate into durable consumables use despite ongoing losses. The Lunit SCOPE IO tie up fits that story by deepening the oncology workflow, although on its own it does not change the near term picture of unprofitability and a high P/S.

The nearer catalyst remains execution on new products like Xenium and Atera, as well as on lower cost consumables that are intended to drive higher reaction volumes. The biggest current risk stays the same. Research budget pressure and discounting on instruments and kits could weigh on revenue mix and delay any path toward earnings improvement.

The Lunit agreement lines up most directly with 10x Genomics efforts around Xenium and Atera. Those platforms are already positioned for in situ and spatial oncology research. Pairing them with AI based pathology gives customers a richer view of tumor biology and treatment response, which may support adoption if users value integrated workflows.

There is a trade off to watch. Management is leaning into lower cost consumables and more complex applications in oncology while still running operating losses and facing price sensitivity from academic and government customers. Your call is whether tighter AI and spatial integration offsets risks from discounting, funding headwinds, and a P/S that screens as expensive.

10x Genomics’ current analyst narrative points to revenues of US$781.5 million and earnings of US$128.8 million by 2029. That profile builds on an assumed 8.2% yearly increase in sales and an earnings swing of about US$203.9 million, from a loss of US$75.1 million today.

Uncover why 10x Genomics' fair value indicates a 36% potential downside to its current price, which leaves little room for error.

Exploring Other Perspectives

One alternate view puts biopharma demand at the center for 10x Genomics. The most optimistic analysts were already penciling in revenue of about US$839.1 million and earnings of US$138.1 million by 2029, with a bullish price target of US$68.25. Those forecasts all predate this AI pathology partnership, so opinions could shift.

Explore 3 other 10x Genomics fair value estimates, including one that suggests it could be worth as much as $68.25.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.

• A great starting point for your 10x Genomics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• See our latest analysis for 10x Genomics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate 10x Genomics' overall financial health at a glance.

Looking for more 10x Genomics style investment ideas?

If this 10x Genomics story has you thinking about where else to apply the same kind of research lens, the Simply Wall St Screener can help you quickly narrow the field to companies that better fit your risk profile and return goals.

• If capital preservation matters most to you, consider starting with 11 resilient stocks with low risk scores that pair sturdier financial profiles with lower volatility.
• For investors hunting for mispriced quality, scan through the 33 high quality undervalued stocks that combine stronger fundamentals with prices that may not fully reflect them.
• If you prefer sturdier balance sheets as a buffer during tougher periods, focus on the list of solid balance sheet and fundamentals (22 results) to see which businesses carry less leverage and more financial flexibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com